The gene editing company published a proof-of-concept for "smart" immunotherapies. The idea may catch on.
The FDA approved the company's schizophrenia drug candidate.
What goes up must come down. But today's tumble means relatively little for investors with a long-term mindset.
The small-cap company announced the pricing of a public stock offering.
It generates more electricity from the wind and sun than any other company on the planet. Does the dividend live up to the renewable energy leader's world-class operations?
Favorable clinical results? Check. Cash from public stock offering? Check.
An early-stage start-up with an improved version of CRISPR gene editing filed to go public. Investors may want to keep an eye on it.
It seems few supporters of low- and zero-carbon technologies are happy with the tax-credit extensions proposed by Congress. What about investors?
An important tax credit will be retroactively reinstated and extended through the end of 2022. It could be worth close to $1.5 billion to the company.
The fuel cell stock has rebounded from recent lows and held onto its gains. Will executing on the latest strategy be enough to send shares higher next year?
If lawmakers hammer out an extension to biodiesel tax credits by the end of the day Monday, then a massive windfall could be headed the company's way.
The synthetic biology pioneer launched an important new product, but it faces immense competition.
The biopharma announced the pricing of a public stock offering.
The generic drug company announced the approval and launch of an important new product.
The drug manufacturing company reported operating results for its fiscal second quarter.
These small-cap biopharma stocks offer intriguing potential in 2020 and beyond.
XBiotech announced a massive deal with Johnson & Johnson subsidiary Janssen, which is thrusting the overlooked biopharma onto the radars of investors.
Investors should remember that CRISPR isn't the only gene editing technology out there. Case in point: ARCUS.
Precision BioSciences provided an expanded update from its first clinical asset. Investors weren't impressed.
A triple-combination therapy from the company triggered responses in 100% of patients with difficult-to-treat blood cancers.